Clinical trial
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
NCT00083694 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00083694 |
|---|---|
| Title | Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia |
| Official title | UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia |
| Lead sponsor | University of Arkansas, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Thalidomide |
| Enrollment | 25 |
| Start date | Aug 1, 1998 |
| Completion | May 1, 2005 |
| First posted | May 31, 2004 |
| Last update posted | Jul 2, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: